Preclinical studies of treosulfan demonstrate potent activity in Ewing’s sarcoma
High-dose chemotherapy with the alkylating agent busulfan has been widely used in the treatment of patients with high-risk Ewing’s sarcoma. Because of risks for toxicity, busulfan and radiotherapy can not be applied together, leading to the omission of one effective therapy component. Treosulfan is a derivative of busulfan which has a lower side effect profile than busulfan and which can be used together with radiotherapy. We investigated the effect of treosulfan in a panel of Ewing’s sarcoma cell lines on cell survival, cell cycle and apoptosis in vitro and compared it to busulfan. Furthermore, the anti-tumor effect of treosulfan was studied in an orthotopic Ewing’s sarcoma mouse xenograft model.
Cell survival was measured by MTT assay and cell cycle analysis by flow cytometry. Apoptosis was analyzed via detection of DNA fragmentation, Hoechst 33258 staining, Annexin V, and cleavage of caspases-3 and 9. The effect of treosulfan and busulfan on primary tumor growth was assessed in Ewing’s sarcoma xenografts in NOD/SCID mice (10 mice per group), pharmacokinetics of treosulfan were analyzed in nude mice.
Treosulfan inhibited cell growth to at least 70% in all cell lines at concentrations achievable in vivo. Treosulfan had a greater effect on the inhibition of cell growth at equivalent concentrations compared to busulfan. The growth inhibitory effect of treosulfan at low concentrations was mainly due to a G2 cell cycle arrest, whereas at higher concentrations it was due to apoptosis. Apoptosis was induced at lower concentrations compared to busulfan. In contrast to busulfan, treosulfan induced cell death in an apoptosis-deficient cell line at concentrations achievable in vivo. In mice, treosulfan suppressed tumor growth at dosages of 2,500 and 3,000 mg/kg. Pharmacokinetic exposures of treosulfan in mice were similar to previous reports in human patients. At maximal tolerated dosages treosulfan had a higher anti-tumor activity than busulfan.
Our results suggest that treosulfan has efficacy against Ewing’s sarcoma cells in vitro and in mice. Therefore, controlled trials examining the role of treosulfan in patients with Ewing’s sarcoma are warranted.
KeywordsEwing’s sarcoma Treosulfan Busulfan Chemosensitivity Apoptosis Mouse Xenograft Pharmacokinetics
Area under the curve
We would like to thank Mwe Mwe Chao, MD for helpful comments. This work was funded by the Forschungskommission of the Faculty of Medicine of the University of Freiburg.
- 3.Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R, Amann G, Dockhorn-Dworniczak B, Harms D, Muller-Weihrich S, Welte K, Kornhuber B, Janka-Schaub G, Gobel U, Treuner J, Voute PA, Zoubek A, Gadner H, Jurgens H (2001) Localized Ewing tumor of bone: final results of the cooperative Ewing’s Sarcoma Study CESS 86. J Clin Oncol 19:1818–1829PubMedGoogle Scholar
- 9.van der Jagt RH, Appelbaum FR, Petersen FB, Bigelow CL, Fisher LD, Schoch GH, Buckner CD, Sanders JE, Storb R, Sullivan KM (1991) Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest radiotherapy. Bone Marrow Transplant 8:211–215PubMedGoogle Scholar
- 12.Koenigsmann M, Mohren M, Jentsch-Ullrich K, Franke A, Becker E, Heim M, Freund M, Casper J (2004) High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation. Bone Marrow Transplant 34:477–483PubMedCrossRefGoogle Scholar
- 13.Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME, Basara N, Fauser AA, Hertenstein B, Mylius HA, Baumgart J, Pichlmeier U, Hahn JR, Holler E (2005) Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 35:233–241PubMedCrossRefGoogle Scholar
- 14.Bitan M, Shapira MY, Resnick IB, Zilberman I, Miron S, Samuel S, Ackerstein A, Elad S, Israel S, Amar A, Fibach E, Or R, Slavin S (2005) Successful transplantation of haploidentically mismatched peripheral blood stem cells using CD133+-purified stem cells. Exp Hematol 33:713–718PubMedCrossRefGoogle Scholar
- 15.Casper J, Wilhelm S, Steiner B, Wolff D, Grobe N, Hahling D, Hartung G, Hilgendorf I, Luck A, Junghanss C, Kahl C, Baumgart J, Pichlmeier U, Freund M (2005) Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine. Dtsch Med Wochenschr 130:2125–2129PubMedCrossRefGoogle Scholar
- 16.Kroger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuk F, Wolschke C, Renges H, Dahlke J, Atanackovic D, Nagler A, Zander A (2006) Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant 37:339–344PubMedCrossRefGoogle Scholar
- 17.Fruehauf S, Buss EC, Tropaly J, Kreipe HH, Ho AD (2005) Myeloablative conditioning in myelofibrosis using i.v. treosulfan and autologous peripheral blood progenitor cell transplantation with high doses of CD34+ cells results in hematologic responses. A follow-up of three patients. Haematologica 90:ECR08Google Scholar
- 18.Markiewicz M, Wojciechowska M, Wylezol I, Wozniczka K, Giebel S, Wojnar J, Krawczyk-Kulis M, Mendek-Czajkowska E, Holowiecki J (2006) Unrelated donor bone marrow transplantation with treosulfan-based myeloablative conditioning for paroxysmal nocturnal hemoglobinuria-successful treatment despite multiple transplant-related risk factors for hemolysis including major Kidd group incompatibility. Bone Marrow Transplant 37:231–232PubMedCrossRefGoogle Scholar
- 19.Wachowiak J, Chybicka A, Kowalczyk J, Boruczkowski D, Gorczynska E, Wojcik B, Leda M, Drabko K, Pieczonka A, Turkiewicz D, Kawak K, Choma M (2005) Retrospective study on treosulfan-based preparative regimen for allogeneic HSCT in children with hematological malignancies and high risk of conventional regimen related toxicity. Bone Marrow Transplant 35(S2):261 (Abstract)Google Scholar
- 20.Drabko K, Zawitkowska-Klaczynska J, Wojcik B, Choma M, Zaucha-Prazmo A, Kowalczyk J, Gorczynska E, Toporski J, Kalwak K, Turkiewicz D, Chybicka A (2005) Megachemotherapy followed by autologous stem cell transplantation in children with Ewing’s sarcoma. Pediatr Transplant 9:618–621PubMedCrossRefGoogle Scholar
- 22.Dirksen U (2007) Treosulfan high dose therapy with autologous stem cell rescue in high-risk Ewing tumors. J Clin Oncol 25(18S):100039 (Abstract)Google Scholar
- 34.Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM, Bornhauser M, Ehninger G, Berdel WE, Baumgart J, Harstrick A, Bojko P, Wolf HH, Schindler AE, Seeber S (2000) Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 6:4209–4216PubMedGoogle Scholar
- 35.Fernandez HF, Tran HT, Albrecht F, Lennon S, Caldera H, Goodman MS (2002) Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant 8:486–492PubMedCrossRefGoogle Scholar
- 36.Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, Green DR (1995) Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 182:1545–1556PubMedCrossRefGoogle Scholar
- 42.Ploemacher RE, Johnson KW, Rombouts EJ, Etienne K, Westerhof GR, Baumgart J, White-Scharf ME, Down JD (2004) Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model. Biol Blood Marrow Transplant 10:236–245PubMedCrossRefGoogle Scholar
- 45.Boland I, Vassal G, Morizet J, Terrier-Lacombe MJ, Valteau-Couanet D, Kalifa C, Hartmann O, Gouyette A (1999) Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations. Br J Cancer 79:787–792PubMedCrossRefGoogle Scholar